Jula Inrig - 24 Dec 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
24 Dec 2025
Net transactions value
-$496,054
Form type
4
Filing time
29 Dec 2025, 21:01:27 UTC
Previous filing
02 Jul 2025
Next filing
07 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Inrig Jula CHIEF MEDICAL OFFICER C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed, Attorney-in-Fact 29 Dec 2025 0001902368

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise $133,950 +15,000 +17% $8.93 103,787 24 Dec 2025 Direct
transaction TVTX Common Stock Sale $630,004 -15,000 -14% $42.00 88,787 24 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -15,000 -16% $0.000000 76,000 24 Dec 2025 Common Stock 15,000 $8.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2 The weighted average sale price for the transaction reported was $42.0003, and the range of prices were between $42.00 and $42.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3 One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.